NCT02685306 - A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | Biotech Hunter

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

September 30, 2017

Conditions

Breast CancerTriple Negative Breast NeoplasmsTriple-Negative Breast NeoplasmTriple-Negative Breast CancerTriple Negative Breast CancerER-Negative PR-Negative HER2-Negative Breast NeoplasmsER-Negative PR-Negative HER2-Negative Breast Cancer

Interventions

BIOLOGICAL

Bavituximab

12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78

DRUG

Taxane

12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78